Direct effect of calcitriol on the regulation of parathyroid hormone secretion in a case of pseudo-hypoparathyroidism (a 24-month follow-up study)

The diagnosis of pseudohypoparathyroidism with osteitis fibrosa was made in a 51-year-old woman on the basis of hypocalcaemia, elevated plasma PTH (1-84) and blunted cAMP response to hPTH infusion. Radiologically, widespread signs of hyperparathyroidism were observed and quantitative histomorphometr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 1995-05, Vol.14 (3), p.287-291
Main Authors: Giraud, P, Audran, M, Rohmer, V, Jallet, P, Basle, M F, Bregeon, C, Bigorgne, J C
Format: Article
Language:English
Subjects:
Biopsy
Calcitriol - therapeutic use
Female
Follow-Up Studies
Humans
Ilium - pathology
Middle Aged
Osteitis Fibrosa Cystica - complications
Osteitis Fibrosa Cystica - diagnostic imaging
Parathyroid Hormone - metabolism
Pseudohypoparathyroidism - complications
Pseudohypoparathyroidism - drug therapy
Pseudohypoparathyroidism - metabolism
Radiography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The diagnosis of pseudohypoparathyroidism with osteitis fibrosa was made in a 51-year-old woman on the basis of hypocalcaemia, elevated plasma PTH (1-84) and blunted cAMP response to hPTH infusion. Radiologically, widespread signs of hyperparathyroidism were observed and quantitative histomorphometry confirmed the increased bone cellular turnover. Treatment with calcitriol (1,25 dihydroxyvitamin D3) induced a dramatic improvement of bone lesions. During treatment PTH (1-84) normalized with high dosage of calcitriol in spite of low or subnormal levels of serum calcium, and subsequently increased for each reduction of calcitriol dosage despite normal calcium levels. Our observations support a major and direct effect of 1,25 dihydroxyvitamin D3 on the regulation of parathyroid secretion of parathyroids glands.
ISSN:0770-3198
1434-9949
DOI:10.1007/bf02208341